About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

TL-895 and KRT-232 Study in Acute Myeloid Leukemia

NCT04669067·35 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Telios Pharma, Inc.

With

Kartos Therapeutics, Inc.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

TP53 wildtype AML
Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor
FLT3 mutation (FLT3-TKD or FLT3-ITD)
ECOG 0-2
Adequate hematologic, hepatic, and renal functions

You may not be if

AML subtype 3
Prior treatment with MDM2 antagonist therapies
Eligible for HSCT

The record

StatusUnknown

PhasePhase 1–2

Taking part18

StartedMar 2021

UpdatedFeb 17, 2023

Conditions

Acute Myeloid Leukemia

Where35

Keck School of Medicine
Los Angeles, California, United States
University of California, Irvine Medical Center
Orange, California, United States
Georgia Cancer Center
Augusta, Georgia, United States

Clareo Health | TL-895 and KRT-232 Study in Acute Myeloid Leukemia